KR101849813B1 - 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 - Google Patents
염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 Download PDFInfo
- Publication number
- KR101849813B1 KR101849813B1 KR1020137018100A KR20137018100A KR101849813B1 KR 101849813 B1 KR101849813 B1 KR 101849813B1 KR 1020137018100 A KR1020137018100 A KR 1020137018100A KR 20137018100 A KR20137018100 A KR 20137018100A KR 101849813 B1 KR101849813 B1 KR 101849813B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- pain
- methanesulfonylpropionitrile
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LQFRYKBDZNPJSW-UHFFFAOYSA-N CS(CCC#N)(=O)=O Chemical compound CS(CCC#N)(=O)=O LQFRYKBDZNPJSW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C255/03—Mononitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42348510P | 2010-12-15 | 2010-12-15 | |
| US61/423,485 | 2010-12-15 | ||
| PCT/US2011/064590 WO2012082718A2 (en) | 2010-12-15 | 2011-12-13 | 3-methanesulfonylpropionitrile for treating inflammation and pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140030122A KR20140030122A (ko) | 2014-03-11 |
| KR101849813B1 true KR101849813B1 (ko) | 2018-04-17 |
Family
ID=46235178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137018100A Active KR101849813B1 (ko) | 2010-12-15 | 2011-12-13 | 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US8476316B2 (https=) |
| EP (1) | EP2651407B1 (https=) |
| JP (1) | JP5932830B2 (https=) |
| KR (1) | KR101849813B1 (https=) |
| CN (1) | CN103260613B (https=) |
| AU (1) | AU2011344030B2 (https=) |
| BR (1) | BR112013014583A2 (https=) |
| CA (1) | CA2820625C (https=) |
| MX (1) | MX2013006708A (https=) |
| TW (1) | TWI522338B (https=) |
| WO (1) | WO2012082718A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6151723B2 (ja) | 2012-02-27 | 2017-06-21 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 3−メチルスルホニルプロピオニトリルを調製するプロセス |
| CA2875052C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Method for treating skin inflammatory diseases |
| JP6208751B2 (ja) * | 2012-06-05 | 2017-10-04 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 炎症及び疼痛を治療するための医薬組成物 |
| US9481644B2 (en) | 2012-06-05 | 2016-11-01 | Olatec Therapeutics Llc | Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile |
| WO2013184703A1 (en) * | 2012-06-05 | 2013-12-12 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| JP6228193B2 (ja) | 2012-06-11 | 2017-11-08 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 炎症及び疼痛を治療するための化合物 |
| US9114122B2 (en) | 2012-06-14 | 2015-08-25 | Olatec Industries Llc | Compounds for treating inflammation and pain |
| WO2013188314A1 (en) * | 2012-06-14 | 2013-12-19 | Olatec Industries Llc | Compounds for treating inflammation and pain |
| PL3369435T3 (pl) | 2013-07-18 | 2020-04-30 | Xalud Therapeutics, Inc. | Kompozycja do leczenia choroby zapalnej stawów |
| JP6461961B2 (ja) | 2013-08-20 | 2019-01-30 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | ジエチル(2−シアノエチル)ホスホネートの医薬組成物および使用 |
| WO2015048328A1 (en) * | 2013-09-26 | 2015-04-02 | Olatec Industries Llc | 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use |
| US9440916B2 (en) | 2013-09-26 | 2016-09-13 | Olatec Therapeutics Llc | 3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use |
| US9999610B2 (en) | 2013-10-01 | 2018-06-19 | Olatec Therapeutics Llc | Pharmaceutical use of 3-benzylsulfonylpropionitrile |
| EP3052475B1 (en) * | 2013-10-01 | 2018-08-08 | Olatec Therapeutics LLC | Pharmaceutical use of 3-benzylsulfonylpropionitrile |
| US9522878B2 (en) | 2013-10-07 | 2016-12-20 | Olatec Therapeutics Llc | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use |
| EP3055286A4 (en) * | 2013-10-07 | 2017-05-24 | Olatec Therapeutics LLC | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use |
| WO2015081188A1 (en) * | 2013-11-27 | 2015-06-04 | Olatec Industries Llc | Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile |
| EP3468530A4 (en) | 2016-06-10 | 2020-03-11 | Clarity Cosmetics Inc. | NON-COMEDOGEN FORMULA FOR HAIR AND SCALP CARE AND METHOD FOR USE |
| ES2970485T3 (es) | 2017-01-06 | 2024-05-29 | Olatec Therapeutics Llc | Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares |
| US10273203B2 (en) | 2017-04-11 | 2019-04-30 | Olatec Therapeutics Llc | Deuterated 3-methanesulfonylpropionitrile |
| WO2019032672A1 (en) * | 2017-08-11 | 2019-02-14 | Olatec Therapeutics Llc | METHOD OF TREATING SCHNITZLER SYNDROME |
| CA3087865A1 (en) | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
| JP7229565B2 (ja) * | 2018-03-21 | 2023-02-28 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | メラノーマを治療するための方法 |
| WO2020241809A1 (ja) * | 2019-05-31 | 2020-12-03 | 日本たばこ産業株式会社 | 幸福感の評価方法及び幸福感を評価するためのデータ取得方法 |
| AU2020296829B2 (en) * | 2019-06-17 | 2026-01-15 | Olatec Therapeutics Llc | Method for treating asthma |
| EP4045009A4 (en) | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| WO2022226495A1 (en) * | 2021-04-22 | 2022-10-27 | Olatec Therapeutics Llc | Method for treating spinal cord injury |
| CN118436631B (zh) * | 2024-05-08 | 2025-07-01 | 中国人民解放军军事科学院军事医学研究院 | 达泮舒腈在预防和/或治疗急性放射性肺损伤中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516879A (ja) | 1998-06-02 | 2002-06-11 | エルジ ケミカル リミテッド | 非ステロイド性消炎鎮痛剤の経皮投与用組成物 |
| US20060069160A1 (en) | 2004-09-24 | 2006-03-30 | Christopher Torrence | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
| WO2007108807A1 (en) | 2006-03-20 | 2007-09-27 | Olatec Industries Llc | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3041155A1 (de) * | 1980-10-31 | 1982-06-09 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen |
| JPS58501722A (ja) * | 1981-10-16 | 1983-10-13 | アボツト ラボラトリ−ズ | 〔1↓−(2↓−ベンゾオキサゾリル)ヒドラジノ〕アルキルニトリル誘導体 |
| US5175192A (en) * | 1984-03-19 | 1992-12-29 | The Rockefeller University | Inhibitors of the advanced glycosylation of proteins and methods of use therefor |
| EP0355049A3 (en) | 1988-08-18 | 1990-06-13 | Zeneca Limited | Heterocyclic compounds |
| US5348838A (en) | 1991-07-31 | 1994-09-20 | Kabushiki Kaisha Toshiba | Photosensitive composition comprising alkali soluble binder and photoacid generator having sulfonyl group |
| WO1999039713A1 (en) | 1998-02-09 | 1999-08-12 | Chong Kun Dang Pharmaceutical Corp. | Piroxicam-containing hydroalcoholic gel composition |
| US6551615B1 (en) * | 2001-10-18 | 2003-04-22 | M/S. Strides Arcolab Limited | Dexibuprofen-containing soft gelatin capsules and process for preparing the same |
| CN1528284A (zh) * | 2003-10-06 | 2004-09-15 | 南昌弘益科技有限公司 | 蔊菜素滴丸及其制备方法 |
| PT1988779E (pt) * | 2006-02-16 | 2015-09-04 | Anacor Pharmaceuticals Inc | Moléculas pequenas contendo boro como agentes antiinflamatórios |
| US20100221337A1 (en) * | 2007-02-14 | 2010-09-02 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist |
| KR20150065941A (ko) * | 2008-03-06 | 2015-06-15 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
| WO2010018814A1 (ja) | 2008-08-12 | 2010-02-18 | 宇部興産株式会社 | 非水電解液及びそれを用いたリチウム電池 |
| AU2010226794A1 (en) * | 2009-03-18 | 2011-10-27 | Olatec Industries Llc | Compounds for treating inflammation and pain |
-
2011
- 2011-12-13 EP EP11849401.2A patent/EP2651407B1/en active Active
- 2011-12-13 BR BR112013014583A patent/BR112013014583A2/pt not_active Application Discontinuation
- 2011-12-13 MX MX2013006708A patent/MX2013006708A/es active IP Right Grant
- 2011-12-13 AU AU2011344030A patent/AU2011344030B2/en active Active
- 2011-12-13 JP JP2013544685A patent/JP5932830B2/ja active Active
- 2011-12-13 CA CA2820625A patent/CA2820625C/en active Active
- 2011-12-13 US US13/324,777 patent/US8476316B2/en active Active
- 2011-12-13 KR KR1020137018100A patent/KR101849813B1/ko active Active
- 2011-12-13 CN CN201180060698.0A patent/CN103260613B/zh active Active
- 2011-12-13 WO PCT/US2011/064590 patent/WO2012082718A2/en not_active Ceased
- 2011-12-15 TW TW100146435A patent/TWI522338B/zh active
-
2013
- 2013-02-05 US US13/759,676 patent/US8829046B2/en active Active
-
2014
- 2014-03-17 US US14/216,664 patent/US8975297B2/en active Active
-
2015
- 2015-03-05 US US14/639,781 patent/US9492420B2/en active Active
-
2016
- 2016-11-11 US US15/349,161 patent/US9770428B2/en active Active
-
2017
- 2017-09-22 US US15/712,269 patent/US10080735B2/en active Active
-
2018
- 2018-09-24 US US16/139,351 patent/US10500184B2/en active Active
-
2019
- 2019-12-05 US US16/704,921 patent/US11229620B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002516879A (ja) | 1998-06-02 | 2002-06-11 | エルジ ケミカル リミテッド | 非ステロイド性消炎鎮痛剤の経皮投与用組成物 |
| US20060069160A1 (en) | 2004-09-24 | 2006-03-30 | Christopher Torrence | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
| WO2007108807A1 (en) | 2006-03-20 | 2007-09-27 | Olatec Industries Llc | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
| JP2009534305A (ja) | 2006-03-20 | 2009-09-24 | オラテック インダストリーズ リミティド ライアビリティ カンパニー | 細菌性疾患、ウィルス性疾患、真菌症、炎症、及び疼痛の治療用組成物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101849813B1 (ko) | 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 | |
| US7851650B2 (en) | Compounds for treating inflammation and pain | |
| EP3048886B1 (en) | 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use | |
| KR20150022976A (ko) | 염증 및 통증 치료를 위한 화합물 | |
| EP3055286A1 (en) | 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use | |
| CN105682460B (zh) | 3,4-双-苄磺酰基丁腈及其药学用途 | |
| EP3052475B1 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20210402 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20220401 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 8 |